High hopes as Inventiva takes NASH contender into phase 3
pharmaphorum
JANUARY 6, 2021
Lanifibranor is also taken orally, making it convenient for patients and Inventiva is hoping to offer a choice of two doses offering doctors the ability lower the strength of the medication to control side-effects such as oedema. billion annually if approved.
52 
Let's personalize your content